Sammons honored for RAD’s sun protection efforts
NEW YORK —The Skin Cancer Foundation on Oct. 6 honored Mary Sammons (pictured), Rite Aid chairman and CEO, with a Skin Sense Award for Rite Aid’s contributions in promoting sun protection. Also recognized was David Greenberg, president and CEO of Maybelline New York-Garnier.
“The Skin Sense Award Gala is always a highlight of the year for the Skin Cancer Foundation. It’s a chance for us to reflect upon our accomplishments, look toward the future and thank those who make our work possible,” stated Perry Robins, the foundation’s president and founder. Since 1994, the Skin Sense Award Gala has honored those who have played a pivotal role in educating the public about the importance of sun protection. This year, the Skin Cancer Foundation is celebrating its 30th anniversary.
In conjunction with the Skin Cancer Foundation’s annual Skin Sense Award Gala, Rite Aid and Garnier in September announced a new marketing campaign to promote the need for daily sun protection. During the months of September and October at Rite Aid, $1 from each sale of Garnier Nutritioniste Skin Renew anti-sun-damage daily moisture lotion SPF 28 and Garnier Nutritioniste Skin Renew anti-sun-damage eye cream SPF 15 will be donated to the Skin Cancer Foundation.
Hy-Vee celebrates the other white meat
WEST DES MOINES, Iowa A lot of people complain about pork barrel spending, but not Midwest supermarket chain Hy-Vee.
October is National Pork Month, and the West Des Moines, Iowa-based Hy-Vee announced Friday that sales of the meat have increased more than 25% over October 2008. The chain said it was on track to increase pork tonnage by more than 30%.
“With pork prices the lowest they’ve been in more than a decade, we’ve focused our marketing efforts on promoting pork as a great value for consumers,” Hy-Vee assistant VP meat operations Kenan Judge said in a statement. “Today’s shopper is looking for nutritious, economical meal ideas, and pork perfectly fits the bill.”
Patients prefer new diabetes drug Victoza over its competitor, survey finds
MONTREAL A new diabetes drug satisfied patients more than its competitor, according to a study funded by the drug’s manufacturer.
According to data on 379 patients who took the Diabetes Treatment Satisfaction Questionnaires, presented Thursday at the 20th World Diabetes Congress and published in medical journal The Lancet, patients taking Novo Nordisk’s drug Victoza (liraglutide) perceived less abnormally low or high blood sugar levels — known respectively as hypoglycemia and hyperglycemia — than those taking Byetta (exenatide), made by Eli Lilly & Co., Amylin Corp. and Alkermes.
Victoza is approved in Europe, but Novo Nordisk is still waiting for approval from the Food and Drug Administration in the United States.
“Liraglutide has shown here in a convincing study that it is associated with less nausea, less perceived hypoglycemia and definitely higher patient satisfaction compared to exenatide,” principal investigator Wolfgang Schmidt said in a statement. “Patient-reported outcomes data is an important extension of the efficacy data. If a patient is satisfied with his or her treatment, then they are much more likely to really stick to the treatment over the long term, which is necessary in Type 2 diabetes.”